Compare PRSO & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | PFSA |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 11.1M |
| IPO Year | 2001 | N/A |
| Metric | PRSO | PFSA |
|---|---|---|
| Price | $0.98 | $0.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 932.8K | ★ 7.7M |
| Earning Date | 11-10-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,001,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.15 | ★ 122.22 |
| 52 Week Low | $0.52 | $0.12 |
| 52 Week High | $2.37 | $12.76 |
| Indicator | PRSO | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | N/A |
| Support Level | $0.92 | N/A |
| Resistance Level | $1.05 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 70.87 | 0.00 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.